

Neurizon Secures Loan Against 2025 R&D Tax Rebate

Highlights:

- **Neurizon® Therapeutics has executed a loan agreement for \$1.5m with specialist R&D financing firm Radium Capital**
- **The loan is secured against a small portion of the expected 2025 R&D Tax Rebate**
- **Provides additional, non-dilutive funding, minimising shareholder dilution while maintaining strong operational momentum**

30 July 2025 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA) (“Neurizon” or “the Company”), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, advises that it has executed a loan agreement for \$1.5m secured against its Australian Federal Government’s R&D Tax Incentive scheme rebate for the 2025 financial year (2025 R&D Tax Rebate).

This loan provides non-dilutive funding on top of Neurizon’s existing cash balance¹, ensuring the company can maintain its pipeline of work in advance of receiving the 2025 R&D Tax Rebate. The funding has been provided by Radium Capital, a specialist R&D financing firm. The loan is repayable from the proceeds of the 2025 R&D Tax Rebate and has an interest rate of 17% per annum and represents less than 30% of the expected 2025 R&D Tax Rebate.

Dr. Michael Thurn, Managing Director and Chief Executive Officer, commented: “We are very pleased to have accelerated a portion of our expected 2025 R&D Tax Rebate through a specialist loan agreement. This non-dilutive funding arrangement enhances our near-term liquidity position and complements our existing healthy cash balance, allowing us to confidently advance our exciting pipeline of work. This type of financing is a highly attractive and capital-efficient funding strategy for Neurizon. We’re pleased to have partnered with Radium Capital to establish a straightforward loan agreement that aligns with our goal of minimising shareholder dilution while maintaining strong operational momentum”

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.
For further information, please contact:

Dr. Michael Thurn
Managing Director and Chief Executive Officer
Neurizon Therapeutics Limited
enquiries@neurizon.com
+61 (3) 9692 7222

Lidija Damjanovic
Head of Marketing and Corporate Affairs
Neurizon Therapeutics Limited
lidija@neurizon.com
+61 (0) 425 700 504

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate access to effective ALS treatments for patients while exploring NUZ-001’s potential for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders.

¹ Neurizon’s cash balance at 30 June 2025 was \$4.161m.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit <https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited